BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22071475)

  • 1. High soluble CD30, CD25, and IL-6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early mycosis fungoides.
    Kadin ME; Pavlov IY; Delgado JC; Vonderheid EC
    J Invest Dermatol; 2012 Mar; 132(3 Pt 1):703-10. PubMed ID: 22071475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
    Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
    Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD30 expression and proliferative fraction in nontransformed mycosis fungoides.
    Edinger JT; Clark BZ; Pucevich BE; Geskin LJ; Swerdlow SH
    Am J Surg Pathol; 2009 Dec; 33(12):1860-8. PubMed ID: 19898220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas.
    Vergier B; de Muret A; Beylot-Barry M; Vaillant L; Ekouevi D; Chene G; Carlotti A; Franck N; Dechelotte P; Souteyrand P; Courville P; Joly P; Delaunay M; Bagot M; Grange F; Fraitag S; Bosq J; Petrella T; Durlach A; De Mascarel A; Merlio JP; Wechsler J
    Blood; 2000 Apr; 95(7):2212-8. PubMed ID: 10733487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of CCR3 and CCR4 Suggests a Poor Prognosis in Mycosis Fungoides and Sézary Syndrome.
    Shono Y; Suga H; Kamijo H; Fujii H; Oka T; Miyagaki T; Shishido-Takahashi N; Sugaya M; Sato S
    Acta Derm Venereol; 2019 Jul; 99(9):809-812. PubMed ID: 31045236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides; a study of 66 cases.
    Fauconneau A; Pham-Ledard A; Cappellen D; Frison E; Prochazkova-Carlotti M; Parrens M; Dalle S; Joly P; Viraben R; Franck F; Ingen-Housz-Oro S; Giacchero D; Jullié ML; Vergier B; Merlio JP; Beylot-Barry M
    Br J Dermatol; 2015 Jun; 172(6):1547-1554. PubMed ID: 25645336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD30+ neoplasms of the skin.
    Duvic M
    Curr Hematol Malig Rep; 2011 Dec; 6(4):245-50. PubMed ID: 21850406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?
    Collins K; Gu J; Aung PP; Nagarajan P; Curry JL; Huen A; Ivan D; Prieto VG; Tetzlaff MT; Duvic M; Miranda RN; Vega F; Torres-Cabala CA
    Virchows Arch; 2021 Aug; 479(2):377-383. PubMed ID: 33604757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders.
    Benner MF; Jansen PM; Meijer CJ; Willemze R
    Br J Dermatol; 2009 Jul; 161(1):121-7. PubMed ID: 19416236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides.
    Talpur R; Sui D; Gangar P; Dabaja BS; Duvic M
    Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):49-56. PubMed ID: 26702474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The relation between clinical features of adult T-cell leukemia/lymphoma and the serum levels of soluble CD25 and CD30].
    Takemoto S; Pornkuna R; Hidaka M; Kawano F
    Rinsho Ketsueki; 2016 Jul; 57(7):848-53. PubMed ID: 27498727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of CD30 transcripts with Th1 responses and proinflammatory cytokines in patients with end-stage renal disease.
    Velásquez SY; Opelz G; Rojas M; Süsal C; Alvarez CM
    Hum Immunol; 2016 May; 77(5):403-10. PubMed ID: 26970513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential SATB1 Expression Reveals Heterogeneity of Cutaneous T-Cell Lymphoma.
    Gao Y; Liu F; Sun J; Wen Y; Tu P; Kadin ME; Wang Y
    J Invest Dermatol; 2021 Mar; 141(3):607-618.e6. PubMed ID: 32771472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of cutaneous lymphoma international prognostic index (CLIPI) for mycosis fungoides and Sézary syndrome.
    Danish HH; Liu S; Jhaveri J; Flowers CR; Lechowicz MJ; Esiashvili N; Khan MK
    Leuk Lymphoma; 2016 Dec; 57(12):2813-2819. PubMed ID: 27104864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
    Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
    Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence linking atopy and staphylococcal superantigens to the pathogenesis of lymphomatoid papulosis, a recurrent CD30+ cutaneous lymphoproliferative disorder.
    Kadin ME; Hamilton RG; Vonderheid EC
    PLoS One; 2020; 15(2):e0228751. PubMed ID: 32049976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble CD30: a possible serum tumor marker for primary effusion lymphoma.
    Michai M; Goto H; Hattori S; Vaeteewoottacharn K; Wongkham C; Wongkham S; Okada S
    Asian Pac J Cancer Prev; 2012; 13(10):4939-41. PubMed ID: 23244086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas Ligand, and killing inhibitory receptors and their relationship with clinical behavior.
    Vermeer MH; van Doorn R; Dukers D; Bekkenk MW; Meijer CJ; Willemze R
    J Clin Oncol; 2001 Dec; 19(23):4322-9. PubMed ID: 11731515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
    Nguyen GH; Olson LC; Magro CM
    Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.